Heptares Therapeutics, a subsidiary of Japanese drugmaker Sosei Group (TYO: 4565), has launched a new research collaboration with one of the world’s leading universities.
The collaboration, focused on apelin receptor in cardiovascular diseases, is with the UK’s University of Cambridge and is part of Heptares’ Orbit initiative to promote and broaden the application of its proprietary structure-based drug design expertise directed at such G protein-coupled receptors (GPCR) to create transformative medicine.
"The apelin receptor is emerging as an exciting new target in the regulation of cardiovascular function and offers a unique approach to treat a number of serious cardiovascular diseases"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze